Market Overview:
The global antibiotics market size reached US$ 49.4 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 62.6 Billion by 2028, exhibiting a growth rate (CAGR) of 3.9% during 2023-2028.
Antibiotics are a group of medicines, such as penicillin, cephalosporin, fluoroquinolone, etc., that inhibit the growth of microorganisms, prevent the replication of parasites, and reduce serious complications of bacterial infections. They are generally administered orally in the form of pills, liquids, tablets, and capsules. They are also available as sprays, creams, ointments, and lotions, which are applied topically on the skin to treat certain acne and other skin diseases. Moreover, antibiotics can be administered through an injection or intravenously (IV) for severe infections according to the signs and symptoms of the patients.
The growing prevalence of infectious diseases, such as malaria, tuberculosis, pneumonia, and acquired immunodeficiency syndrome (AIDS), along with the easy availability of generic medicines, represents one of the major factors positively influencing the demand for antibiotics. Moreover, the topical application of antibiotics offers reduced potential for systemic absorption and toxicity and minimizes the risk of surgical site infections. Consequently, the rising number of surgical procedures is increasing the sales of antibiotics to prevent incision infection. They can also be utilized in the form of drops for conjunctivitis and acute ear infections. Furthermore, antibiotics are finding extensive application in livestock farming to safeguard animal health and welfare and support food safety. Apart from this, scientists are developing less reactogenic, cell-free vaccines consisting of purified components, inactivated toxins, and proteins. Additionally, several health organizations are entering into strategic partnerships with private companies to deliver new treatments and improve existing drugs.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global antibiotics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on action mechanism, drug class, spectrum of activity, route of administration and end user.
Breakup by Action Mechanism:
- Cell Wall Synthesis Inhibitors
- Protein Synthesis Inhibitors
- DNA Synthesis Inhibitors
- RNA Synthesis Inhibitors
- Mycolic Acid Inhibitors
- Others
Breakup by Drug Class:
- Cephalosporin
- Penicillin
- Fluoroquinolone
- Macrolide
- Carbapenem
- Aminoglycoside
- Others
Breakup by Spectrum of Activity:
- Broad-Spectrum Antibiotics
- Narrow-Spectrum Antibiotics
Breakup by Route of Administration:
- Oral
- Parenteral
- Topical
- Others
Breakup by End User:
- Hospitals
- Specialty Clinics
- Others
Breakup by Region:
- North America
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Allergan Plc (AbbVie Inc.), Basilea Pharmaceutica AG, GlaxoSmithKline Plc, Johnson & Johnson, Melinta Therapeutics, Merck & Co. Inc., Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Spero Therapeutics and Tetraphase Pharmaceuticals.
Report Coverage:
Report Features |
Details |
Base Year of the Analysis |
2022 |
Historical Period |
2017-2022 |
Forecast Period |
2023-2028 |
Units |
US$ Billion |
Segment Coverage |
Action Mechanism, Drug Class, Spectrum of Activity, Route of Administration, End User, Region |
Region Covered |
Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered |
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered |
Allergan Plc (AbbVie Inc.), Basilea Pharmaceutica AG, GlaxoSmithKline Plc, Johnson & Johnson, Melinta Therapeutics, Merck & Co. Inc., Nabriva Therapeutics Plc, Paratek Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Spero Therapeutics and Tetraphase Pharmaceuticals |
Customization Scope |
10% Free Customization |
Report Price and Purchase Option |
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499 |
Post-Sale Analyst Support |
10-12 Weeks |
Delivery Format |
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
Key Questions Answered in This Report:
- How has the global antibiotics market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global antibiotics market?
- What are the key regional markets?
- What is the breakup of the market based on the action mechanism?
- What is the breakup of the market based on the drug class?
- What is the breakup of the market based on the spectrum of activity?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global antibiotics market and who are the key players?
- What is the degree of competition in the industry?